Health Care & Life Sciences » Pharmaceuticals | Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
19.00
2.00
-
-
-
Cost of Goods Sold (COGS) incl. D&A
-
-
331.00
393.00
658.00
Gross Income
-
-
331.00
393.00
658.00
SG&A Expense
8,711.00
16,037.00
14,893.00
14,267.00
11,365.00
EBIT
9,000.00
16,363.00
15,224.00
14,660.00
12,023.00
Unusual Expense
6,444.00
-
1,091.00
21,256.00
3,831.00
Non Operating Income/Expense
2,888.00
3,783.00
15.00
46.00
353.00
Interest Expense
305.00
3,404.00
827.00
1,555.00
3,655.00
Pretax Income
5,749.00
23,550.00
17,157.00
37,517.00
19,862.00
Income Tax
11.00
-
-
4,856.00
1,973.00
Consolidated Net Income
5,760.00
24,166.00
17,157.00
32,661.00
17,889.00
Net Income
5,760.00
24,166.00
17,157.00
32,661.00
17,889.00
Net Income After Extraordinaries
5,760.00
24,166.00
17,157.00
32,661.00
17,889.00
Net Income Available to Common
6,692.00
24,422.00
24,116.00
40,634.00
24,753.00
EPS (Basic)
18.80
29.20
18.00
9.58
2.11
Basic Shares Outstanding
354.40
837.10
1,337.10
4,240.10
11,755.70
EPS (Diluted)
18.88
29.17
18.04
9.58
2.11
Diluted Shares Outstanding
354.40
837.10
1,337.10
4,240.10
11,755.70
EBITDA
8,692.00
16,035.00
14,893.00
14,267.00
11,365.00
Other After Tax Income (Expense)
-
616.00
-
-
-
Preferred Dividends
932.00
256.00
6,959.00
7,973.00
6,864.00

About Immune Pharmaceuticals

View Profile
Address
550 Sylvan Avenue
Englewood Cliffs New Jersey 07632
United States
Employees -
Website http://www.immunepharma.com
Updated 09/14/2018
Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases.

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.